LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

LLY

1,045.57

+3.75%↑

JNJ

230.89

+0.15%↑

ABBV

214.62

+0.91%↑

UNH

383.23

+0.51%↑

AZN

190.15

+1.08%↑

Home・Akcijų sąrašas・Sana Biotechnology Inc

Sana Biotechnology Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

3.13 0.64

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.01

Max

3.16

Pagrindiniai rodikliai
By Trading Economics
Pajamos	12M -47M
Pelnas, tenkantis vienai akcijai	-0.171
Darbuotojai	142
EBITDA	23M -35M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+183.66% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-115M 846M
Ankstesnė atidarymo kaina	2.49
Ankstesnė uždarymo kaina	3.13

Naujienos nuotaikos

By Acuity

25%

75%

55 / 345 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

1.68 / 1.87 Palaikymas ir pasipriešinimas

Sana Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-20 23:31; UTC

Karštos akcijos

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

2026-05-20 22:52; UTC

Pagrindinės rinkos jėgos

Osisko Shares Fall on Planned Convertible Notes Offering

2026-05-20 23:47; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-20 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

2026-05-20 23:44; UTC

Uždarbis

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

2026-05-20 23:35; UTC

Rinkos pokalbiai

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

2026-05-20 23:30; UTC

Rinkos pokalbiai

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

2026-05-20 23:17; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-20 23:17; UTC

Rinkos pokalbiai

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

2026-05-20 23:15; UTC

Rinkos pokalbiai

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

2026-05-20 23:14; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

2026-05-20 23:02; UTC

Rinkos pokalbiai

KMD Brands Faces Two Testing Hurdles -- Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Infratil's Other Assets Deserve Attention, Too -- Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-05-20 22:57; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-20 22:51; UTC

Rinkos pokalbiai

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

2026-05-20 22:51; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-20 22:27; UTC

Rinkos pokalbiai

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

2026-05-20 22:14; UTC

Rinkos pokalbiai

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

2026-05-20 22:10; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

2026-05-20 22:00; UTC

Uždarbis

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

2026-05-20 21:38; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

2026-05-20 21:27; UTC

Uždarbis

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

2026-05-20 21:20; UTC

Uždarbis

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

2026-05-20 21:19; UTC

Uždarbis

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

2026-05-20 21:18; UTC

Uždarbis

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

2026-05-20 21:17; UTC

Uždarbis

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

2026-05-20 21:17; UTC

Uždarbis

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

2026-05-20 21:17; UTC

Uždarbis

Nvidia's Vera CPU Opens New $200B Market, CFO Says

2026-05-20 21:16; UTC

Uždarbis

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Sana Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

183.66% į viršų

12 mėnesių prognozė

Vidutinis 8.68 USD 183.66%

Aukščiausias 16 USD

Žemiausias 3.07 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sana Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Sana Biotechnology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.68 / 1.87Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Rinkos nuotaikos

By Acuity

55 / 345 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.